level to 65 percent.
These changes represent significant wins for coverage and payment of innovative medical devices and are the latest in a series of payment policy victories that are the result of our multi-year advocacy efforts.
Key highlights of the final rule include the following:
- Alternative NTAP Pathway for Breakthrough Devices and QIDPs
- Change to the Calculation of the NTAP Payment Amount
- Clarifications to the Substantial Clinical Improvement Criterion
- New Technology Add-On Payments (NTAPs) Applications
- Antimicrobial Resistance Diagnoses as Complications and Comorbidities
- Payment Rate Update
Read the Press Release/Fact Sheet.